GLP-1 Medication Shows Potential for Mental Health Treatment

Emerging data suggest that GLP-1 medications, commonly used for managing obesity and type 2 diabetes, may also benefit individuals suffering from certain mental health disorders, particularly depression and substance use disorders, though caution is warranted for use in eating disorders.

Potential Mental Health Benefits of GLP-1 Medications

GLP-1 medications have been recognized for their effectiveness in treating overweight, obesity, and type 2 diabetes. Recent research indicates these medications may also provide therapeutic benefits for some psychiatric conditions. Individuals with diabetes and obesity are often at heightened risk for developing mood disorders, including depression and anxiety. Notably, Taipale (2026) emphasized that these co-morbidities can exacerbate overall health.

Research Findings on Depression and Substance Use Disorders

Studies have shown promising results regarding the use of GLP-1 drugs for alleviating depressive symptoms. Gunturu (2024) reported improvements in depression scores among patients treated with GLP-1 compared to those receiving a placebo. Additionally, GLP-1 has demonstrated neuroprotective properties (Cooper, 2023). Conversely, a trial by Kornelius (2024) investigating obese subjects did not find benefits concerning depression prevention, indicating a need for further exploration of GLP-1’s effects on depressive conditions.

Evidence supporting GLP-1 medications extends to treating substance use disorders as well. Research highlights that these drugs have the potential to reduce alcohol consumption, with one study finding that low-dose semaglutide led to fewer drinks per day and decreased weekly cravings (Hendershot, 2025). Similarly, Klausen (2022) reported a significant reduction in heavy drinking days among a subset of obese patients. The overall effectiveness seems greater in overweight and diabetic individuals when addressing substance use issues (Marquez-Meneses, 2025).

Considerations and Limitations for Use in Eating Disorders

While the role of GLP-1 medications in treating binge eating disorder (BED) is still inconclusive, existing studies suggest a reduction in binge eating in overweight individuals (Himmerich, 2024). However, concerning trends have emerged where individuals misuse GLP-1 medications as a means to manage eating disorders like anorexia or bulimia, which is an unsafe practice (Peiper, 2026). Consequently, GLP-1 medications should not be utilized for eating disorders outside of clinical trials.

Further significant findings indicate that GLP-1 does not increase the risk of suicidal ideation or behavior, addressing past concerns raised during its initial surveillance by the FDA (Drug Safety Communication, 2026; Pierret, 2025).

THE CNP TAKEAWAY

GLP-1 medications may offer robust support for those dealing with depression and substance use disorders, but careful consideration is essential, especially regarding their application in eating disorders. Ongoing research will help clarify optimal usage guidelines.

Images courtesy of Shutterstock.

This article was prepared by The Center for Nutritional Psychology based on the article entitled “Surprising Mental Health Effects of GLP-1 Weight Loss Drugs,” authored by Peter M. Hartmann, MD, DLFAPA. Read psychologytoday.com